Abstract
Background: Early-life immune deviation is suspected in the inception of atopic disease.
Objective: We wished to investigate the association between cord blood chemokines and the subsequent development of atopic biomarkers and clinical end-points during the first 6 years of life.
Methods: The Th1-associated chemokines CXCL10 and CXCL11 and the Th2-associated chemokines CCL17 and CCL22 were assessed in cord blood of asymptomatic at-risk newborn children from the Copenhagen Prospective Study on Asthma in Childhood (COPSAC2000) birth cohort and associated to the longitudinal development of biomarkers and clinical end-points of asthma, eczema and allergic rhinitis during the first 6 years of life.
Result: Cord blood CCL22 levels were significantly associated to total IgE levels measured at 4 time-points during the first 6 years of life; overall odds ratio, 1.54 [CI, 1.25-1.89; P<0.0001].
CXCL10 and CXCL11 were not associated to development of any atopic disorders or biomarkers.
Conclusion and clinical relevance:
High cord blood levels of the Th2 related chemokine CCL22
were significantly associated to high total IgE levels during the first 6 years of life, but not to specific sensitization, asthma, eczema or allergic rhinitis. This suggests an inborn skewing of the immune system in healthy newborns developing elevated total IgE later in life.
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INTRODUCTION
The "atopic diseases" asthma, eczema and allergic rhinitis origin early in life, presumably as a result of a Th2 skewing of the immune system [1, 2] . It is important to understand early-life immune mechanisms responsible for the inception of atopic disease in order to unravel disease pathogenesis towards preventive measures and possibly customized therapies.
Cord blood is easily accessible at birth and provides a unique opportunity to investigate the immunity of the new-born prior to disease onset. Circulating levels of Th1 and Th2 cytokines are difficult to measure in cord blood due to low levels close to the detection limit of the currently available assays [3] . Challenge models generate an exaggerated and possibly unphysiological response. Chemokines are simple to measure with current technology and are equally robust markers of Th1/Th2 immunity [4] [5] [6] [7] [8] in manifest atopic disorders. However, little is known about cord blood Th1-and Th2-related chemokine levels [4, 9] . We hypothesized that Th2 related chemokines in the cord blood are associated to the development of atopic disease and biomarkers during preschool age.
The aim of this work was to investigate the association between the cord blood chemokines Thymus and activation regulated chemokine, TARC (CCL17), Macrophage-derived chemokine, MDC (CCL22), interferon gamma-induced protein 10 kDa, IP-10 (CXCL10) and Interferoninducible T-cell alpha chemoattractant, I-TAC (CXCL11) in asymptomatic at-risk newborn children from the Copenhagen Prospective Study on Asthma in Childhood (COPSAC2000) birth cohort in relation to the subsequent development of atopic biomarkers and clinical end-points during the first 6 years of life.
METHODS
The study is reported in accordance with the STROBE guidelines for observational studies [10] .
Study population
Participants comprised children from the COPSAC2000 cohort of 411 children born of mothers with doctor-verified asthma, the recruitment of whom was previously described in detail [11] .
The pregnant women visited the COPSAC research centre during pregnancy for information on the study procedures. Key exclusion criteria were gestational age <36 weeks, severe congenital abnormality, neonatal mechanical ventilation or symptoms of lower airway infection before one month of age. Consenting mothers brought their one-month-old child to the research clinic and subsequently attended the clinic at six-monthly intervals and immediately upon onset of any allergy-, respiratory-or skin-related symptom until age 7 years.
Ethics
The study was conducted in accordance with the guiding principles of the Declaration of Helsinki and approved by the Ethics Committee for Copenhagen (KF 02-118/98) and the Danish Data Protection Agency (1998-1200-359). Data validity was assured by compliance with Good Clinical Practice guidelines and quality control procedures.
Cord blood collection and analyses
The midwives received written instructions on the collection of cord blood by needle puncture from the umbilical cord vein: 14 ml cord blood was collected (7 ml in an EDTA tube and 7 ml whole blood) and subsequently send to the COPSAC research unit, where the blood was centrifuged for 10 min at 4300 rpm to separate serum and plasma, and thereafter frozen at -80 o C until analysis at the Department of Clinical and Experimental Medicine, Linköping University, Sweden. The chemokines CXCL10, CXCL11, CCL17 and CCL22 were analysed with an in-house multiplexed Luminex assay, as described in detail previously [4] . The limit of detection was 6 pg/ml for CXCL10, 28 pg/ml for CXCL11, and 2 pg/ml for CCL17 and CCL22.
All samples were analysed in duplicates and the sample was re-analysed if the coefficient of variation (CV) was >15%.
Atopic biomarkers
Blood was collected from the children at ages 6 months, 18 months, 4 years and 6 years during visits at the research unit. All samples were stored at -80 o C until analysis.
Total IgE levels were measured at age 6 months, 18 months, 4 years and 6 years by ImmunoCAP (Pharmacia Diagnostics AB, Uppsala, Sweden) with a detection limit of 2 kU/l.
Specific IgE levels against 15 common inhalant and food allergens (cat, dog, horse, birch, timothy grass, mugwort, house dust mites, moulds, hen's egg, cow's milk, fish, wheat, peanut, soybean, or shrimp) were measured at age 6 months, 18 months, 4 years and 6 years by ImmunoCAP (Pharmacia Diagnostics AB, Uppsala, Sweden) [12, 13] .
Skin Prick Test was performed at 6 months, 18 months, 4 years and 6 years against 18 common inhalant and food allergens (birch, timothy grass, mugwort, horse, dog, cat, house dust mites, moulds, hen's egg, cow's milk, fisk, wheat, rye, oat, peanut, soyabean, beef and pork) with standard allergen solutions from ALK-Abelló ® and additionally with pasteurised, fresh products for cow's milk and hen's egg.
Allergic sensitization was defined as specific IgE ≥ 0.35 kU/l [12, 13] for any of the tested allergens and/or a positive skin prick test defined as a wheal ≥2 mm at 6 and 18 months or ≥ 3 mm at 4 or 6 years. Allergic sensitization was analysed as a dichotomized measurement.
Blood eosinophil count (10 9 cells/l) was assessed at age 6 months, 18 months, 4 years and 6 years.
Nasal eosinophilia was examined by nasal scrapings in the child's 6 th year of life and rated according to Meltzer's semi-quantitative scale [14] as previously detailed [15] .
Investigator-diagnosed Clinical End-points
Allergic rhinitis was diagnosed at age 6 by the COPSAC doctors, based on parent interviews on symptom history in the child's 6 th year of life [15] . Rhinitis was defined as troublesome sneezing or blocked or runny nose in the past 12 months in periods without accompanying virus symptoms [16] . Allergic rhinitis was diagnosed in children sensitized to inhaled allergens of relevance to the symptomatic periods.
Asthma at age 7 years was diagnosed as previously detailed, [17, 18] and was based on a history of recurrent wheeze; symptom character judged by the study physicians to be typical of asthma; response to trials of inhaled corticosteroids; and relapse when stopping treatment.
Eczema during the first 6 years of life was diagnosed using the Hanifin-Rajka criteria as previously detailed [19] . Skin lesions were described at both scheduled and acute visits according to pre-defined morphology and localization.
Statistical Analysis
We investigated the association between cord blood levels of the chemokines CXCL10, CXCL11, CCL17, CCL22 and the Th2/Th1 ratios CCL22/CXCL10, CCL17/CXCL10, CCL22/CXCL11, CCL17/CXCL11, and the development of atopic biomarkers and atopic clinical end-points during the first 6 years of life. Models using general estimating equations (GEE; PROC GENMOD in SAS version 9.1) were applied to compute the overall odds ratio for allergic sensitization, blood eosinophil count and total-IgE using compiled data from all four measuring points (6 months, 18 months, 4 years and 6 years). Logistic regression was used to calculate odds ratios of the cross-sectional end-points allergic rhinitis, nasal eosinophilia, and asthma. Hazard ratios of recurrent wheeze and eczema at age 0-1 year and 0-6 year were calculated by Cox regression. Age at onset was modelled as a function of chemokine levels and ratios; the children were retained in the analysis from birth until age at onset of disease, dropout, or age at end of the observation period (i.e. 1 year for 0-1 year), whichever first. Levels of chemokines, total IgE, and blood eosinophilia were log-transformed prior to analysis.
Results are reported with 95% CI in brackets. Robustness of results was investigated by adjusting for multiple testing according to the method by Bonferoni correction for control of false discovery rate. All analyses were done in SAS version 9.1 for Windows (SAS Institute, Inc., Cary, NC).
RESULTS:
Baseline Cord blood samples were available for analyses from 223 of the 411 children from the COPSAC2000 cohort. Children from low-income families were significantly less likely to have cord blood sampled [P-value = 0.008], whereas there were no differences between children with and without cord blood samples with respects to ethnicity, exposure to tobacco, alcohol and maternal antibiotic use during 3 rd trimester, mode of delivery, gestational age, gender or anthroprometrics ( Table 1) .
Levels of chemokines, total-IgE, blood eosinophil count and frequency of nasal eosinophilia, allergic rhinitis, asthma, eczema and allergic sensitization in the study group are outlined in Table 2 .
Association between cord blood chemokine levels and atopic biomarkers Total-IgE: Cord blood CCL22 levels were significantly associated to total IgE levels at 6 months, 18 months, 4 years and 6 years (GEE model including all 4 measuring points): odds ratio, 1.54 [CI, 1.25-1.89; P<0.0001]. In addition, the Th2/Th1 ratios were also associated to Total IgE levels: CCL22/CXCL11: odds ratio, 1.31 [CI, 1.13-1.51; P= 0.0002] and CCL22/CXCL10 odds ratio, 1.22 [CI, 1.03-1.43; P=0.02]. However, the CCL22/CXCL10 ratio did not pass the Bonferroni threshold for significance (Table 3 ). There was no association between CCL17, CXCL11 or CXCL10 and Total IgE levels. Figure 1 shows the individualized association between cord blood CCL22 and total IgE at each measured time-point.
Specific IgE: No association was found between specific IgE and any cord blood chemokine levels (Table 3) .
Blood eosinophil count:
Cord blood CCL22 and CXCL11 levels were associated with development of blood eosinophilia in the overall GEE model: Odds ratio, 1.15 [CI, 1.00-1.32; P= 0.05] and odds ratio, 1.09 [CI, 1.00-1.20; P=0.05], respectively. However, this was not significant after correction for multiple testing. There was no association between CCL22/CXCL10, CCL22/CXCL11, CCL17/CXCL10, CCL17/CXCL11 ratios, CXCL10 or CCL17, and blood eosinophilia (Table 3) .
Nasal eosinophilia at age 6 years was not associated with any of the tested chemokines or Th2/Th1 ratios (Table E1 online).
Association between cord blood chemokine levels and Investigator-diagnosed Clinical End-points
No association was found between levels or ratios of any of the tested cord blood chemokines and development of eczema, asthma, troublesome lung symptoms or allergic rhinitis during the first 6 years of life (Tables E2 to E5 online).
DISCUSSION:
Principle findings Cord blood levels of the Th2 related chemokine CCL22 and Th2/Th1 chemokine ratios in healthy newborns from the Danish COPSAC2000 birth cohort of asthmatic mothers were significantly associated with total IgE levels during the first 6 years of life. This suggests an inborn/intrauterine Th2 skewing of the immune system in children subsequently developing high levels of total IgE.
Strengths and limitations
The major strength of this study is the 6-year longitudinal, stringent and uniform clinical follow-up of a birth cohort. COPSAC is a single-center study where the COPSAC doctors act as general practitioners for the children, diagnosing and treating all airway-, allergy-and skinrelated symptoms according to predefined algorithms thus assuring consistency in diagnoses and reducing the risk of misclassification.
In addition, the atopic biomarkers; blood eosinophil count, specific-and total-IgE were assessed repeatedly at 4 time points till 6 years of age, increasing the statistical power to detect true associations in GEE models accounting for repeated within subject measurements.
A further strength of the study is the sensitivity of the chemokine assays allowing assessment of chemokine levels in all available cord blood samples without stimulation, thus avoiding excessive un-physiological responses accompanying challenge models. Circulating Th1-and Th2-associated chemokine levels can be used as markers for the Th1/Th2 balance [4] [5] [6] [7] [8] making immune-regulatory chemokines potential biomarkers of current and future disease [20] . Th1 responses increase the levels of CXCR3 ligands CXCL10 and CXCL11, while Th2 responses enhance the levels of CCR4 ligands CCL17 and CCL22. [21, 22] CXCR3 is preferentially expressed on Th1 cells and CCR4 on Th2 cells, thus further amplifying Th1 and Th2 immunity, respectively [22] .
Finally, the large cord blood sample size of 223 samples increases the validity of the data.
Cord blood biomarkers may be biased by transfer from maternal blood. This has been demonstrated for specific and total IgE where maternal levels are often 1000 times higher than cord blood levels and even minimal amount of maternal blood may significantly affect cord blood levels [23, 24] . Such bias from maternal transfer seems not to be an issue for cord blood chemokines that are often found in higher level in cord blood than maternal blood.
A limitation of our study is the high-risk nature of the COPSAC2000 cohort where all mothers have a history of asthma which requires replication in an unselected population. However, the analyses were based on within subject associations between cord blood chemokine levels and the subsequent development of atopic disease and atopic biomarkers unlikely to be affected by the increased risk of atopic diseases. This is supported by a previous study where elevated cord blood CCL22 levels preceded development of sensitisation independent of atopic heredity [9] .
A further limitation is that cord blood samples were only available from half of the cohort.
However, the selected cohort was representative of the main cohort for the majority of population characteristics.
Interpretation
Elevated cord blood levels of the CCL22 chemokine preceding development of raised total IgE during the first 6 years of life suggests a triggering role of CCL22 in the inception of elevated total IgE in children on an atopic trajectory. The mechanism responsible for the linkage between elevated CCL22 and raised total IgE is unknown, though CCL22 is described to play a central role in enhancing the Th2 responses. Thus, our data support the general hypothesis of an early life Th2 skewing of the immune response [1, 3] .
Cord blood CCL22 levels have previously been proposed as a predictor of elevated IgE levels and clinically manifest allergy development [6, 25] . However, only a few others have studied un-stimulated cord blood chemokines. Our findings are supported by a previous report from 56 children where cord blood CCL22 was associated with elevated IgE levels at age 6 [9] . We found no association between cord blood chemokine levels and development of atopic symptoms of asthma, rhinitis or eczema. It is possible that CCL22 is involved in a specific immunological mechanism only causing elevated total IgE but not specific sensitization or disease. Cord blood CCL17 and CCL22 have been associated to atopic dermatitis and asthma development in cohorts of mixed atopic and non-atopic parental predisposition [9, 26] . Since this study is the largest to date, it is possible that previously reported association to atopic disease were the result of a type 1 error. The discrepancy between these findings and our data might also be due to the high-risk nature of the COPSAC2000 cohort.
The mechanism behind elevated cord blood CCL22 remains unclear. However, such pronounced Th2/Th1 imbalance in the newborn may be driven by genetic variants and/or caused by unknown intrauterine environmental triggers impacting the fetal development.
We have previously shown that urine eosinophil protein X in neonates precedes development of allergic sensitization and eczema, [27] and that raised exhaled nitric oxide in neonates associates with development of early transient wheeze [28] . Importantly, these findings and the current study supports the concept of early immunological programming of immune function plays an essential role in the skewing of the immune response. Together such finger-prints of atopic disease development in new-borns may contribute to construction of clinically feasible prediction models in the future.
Conclusion:
High cord blood levels of the Th2 related chemokine CCL22 were significantly associated to high total IgE levels during the first 6 years of life. This suggests an inborn Th2 skewing of the immune system in healthy newborns developing elevated total IgE later in life.
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